Aeolus Pharmaceuticals, Inc.
https://www.aeoluspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aeolus Pharmaceuticals, Inc.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.
Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?
CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.
Mirador Lands $400m To Pursue I&I Precision Medicine Approach
Ex-Prometheus team will use its big data platform to validate targets, select indications and optimize trial enrollment in the development of precision therapies for inflammatory and immune disorders.
EMA Decision Time For Aztreonam-Avibactam; High-Stakes Meeting For Lecanamab
The European Medicines Agency is this week deciding whether a number of new drugs should win EU approval.
Company Information
- Industry
- Distributors
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Incara Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice